First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

Inclusion Criteria: * Willing and able to give written informed consent for participation in the trial. * Healthy male or female subject aged 18-55 years inclusive. * Weight of at least 50 kg and no more than 110 kg at screening. * Willing to use highly effective methods of contraception Exclusion Criteria: * History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the trial, or influence the results or the subject's ability to participate in the trial. * History or present clinically significant psychiatric diagnosis, at discretion of the Investigator. * Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent). * History of seizures, including febrile seizure in childhood. * Any clinically significant illness, medical/surgical procedure or trauma within four (4) weeks of the first administration of IMP. * Any planned major surgery within the duration of the trial. * Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency Virus (HIV). * After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges: Systolic blood pressure \> 140 mm Hg, Diastolic blood pressure \> 90 mm Hg, Heart rate \< 40 or \> 85 beats per minute. * Prolonged QT…